Fri, Dec 19, 2014, 10:14 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • frogsleapmerlot frogsleapmerlot Mar 21, 2004 5:33 PM Flag


    This is a stock that will trade @50 to 60 times earnings, so a $120M to the bottom line will do just that. Thats about a $6 Billion market cap on $500M in sales after 50/50 split on a $1 Billion in sales projected by FY2007. Projections on the seize of the insomnia market is $5 Billion by FY2010. So IMO Indiplon could have sales in the $2 Billion range by FY2010.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Keep in mind, NBIX is a 1-trick pony biotech for the forseeable future. The number of BTs with 1 product that can carry a 60 multiple are limited, the reason being the discount the street needs to afford a company with that kind of business risk. Even with PFE as a partner, the chances of Indiplon ramping to 1B in sales in 3 years with Estorra, Ambien MR and generic Ambien on the market is at best a stretch.

24.49+0.59(+2.47%)Dec 19 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.